Mattson R H
Department of Neurology, Yale University School of Medicine, New Haven, CT 06510, USA.
Neurology. 1998 Nov;51(5 Suppl 4):S15-20. doi: 10.1212/wnl.51.5_suppl_4.s15.
Optimal treatment of epilepsy in adults requires a tailored approach that weighs the efficacy of individual drugs in the specific diagnosis against the patient's risks for adverse events. Partial seizures, which are the most common seizure type in adults, can be effectively controlled by virtually all the standard and newer antiepileptic drugs (AEDs). For the generalized epilepsies, valproate remains the drug of choice. Data continue to accumulate regarding use of the newer agents. Overall, many of the newer AEDs may offer a better tolerability than the standard agents because of more favorable pharmacokinetic characteristics and lack of interactions with drugs other than AEDs. Serious adverse events have been associated with felbamate and lamotrigine, however, and more experience is needed with many of the other newer AEDs to better define their safety profiles. Monotherapy should be the goal when AED treatment is instituted for the adult with epilepsy. Dosage modification on the basis of seizure control and toxicity should be implemented, as well as single-drug trials with alternative AEDs, before resorting to polytherapy. With the introduction of several promising newer AEDs, safe and effective seizure control may become a reality for an increasing number of adults with epilepsy.
成人癫痫的最佳治疗需要一种量身定制的方法,这种方法要权衡特定诊断中各药物的疗效与患者发生不良事件的风险。部分性发作是成人中最常见的发作类型,几乎所有标准及新型抗癫痫药物(AEDs)均可有效控制。对于全身性癫痫,丙戊酸盐仍是首选药物。关于新型药物的使用,数据仍在不断积累。总体而言,许多新型AEDs可能比标准药物耐受性更好,因为它们具有更有利的药代动力学特征,且与AEDs以外的药物无相互作用。然而,苯巴比妥和拉莫三嗪已被证实会引发严重不良事件,对于许多其他新型AEDs,还需要更多经验来更好地明确其安全性。当对成年癫痫患者开始进行AED治疗时,应以单药治疗为目标。在采用联合治疗之前,应根据癫痫发作控制情况和毒性进行剂量调整,并对替代AEDs进行单药试验。随着几种有前景的新型AEDs的引入,对于越来越多的成年癫痫患者来说,安全有效地控制癫痫发作可能会成为现实。